63 related articles for article (PubMed ID: 16844430)
1. Identification of prognostic biomarkers for antibiotic associated nephrotoxicity in cystic fibrosis.
Hart A; Cesar F; Zelnick LR; O'Connor N; Bailey Z; Lo J; Van Ness K; Stanaway IB; Bammler TK; MacDonald JW; Thau MR; Himmelfarb J; Goss CH; Aitken M; Kelly EJ; Bhatraju PK
J Cyst Fibros; 2024 Mar; 23(2):293-299. PubMed ID: 37949747
[TBL] [Abstract][Full Text] [Related]
2. Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis.
Madaule J; Valenzuela F; Mittaine M; Gallois Y; Baladi B; Murris M; Calmels MN; Concordet D; Gandia P
J Cyst Fibros; 2023 Sep; 22(5):944-948. PubMed ID: 37088635
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.
Dong M; Rodriguez AV; Blankenship CA; McPhail G; Vinks AA; Hunter LL
J Antimicrob Chemother; 2021 Oct; 76(11):2923-2931. PubMed ID: 34379758
[TBL] [Abstract][Full Text] [Related]
4. The use of lysosomal enzymuria in the early detection and monitoring of the progression of diabetic nephropathy.
Gatsing D; Garba IH; Adoga GI
Indian J Clin Biochem; 2006 Sep; 21(2):42-8. PubMed ID: 23105612
[TBL] [Abstract][Full Text] [Related]
5. Overview of Antibiotic-Induced Nephrotoxicity.
Campbell RE; Chen CH; Edelstein CL
Kidney Int Rep; 2023 Nov; 8(11):2211-2225. PubMed ID: 38025228
[TBL] [Abstract][Full Text] [Related]
6. Mapping Adverse Outcome Pathways for Kidney Injury as a Basis for the Development of Mechanism-Based Animal-Sparing Approaches to Assessment of Nephrotoxicity.
Mally A; Jarzina S
Front Toxicol; 2022; 4():863643. PubMed ID: 35785263
[TBL] [Abstract][Full Text] [Related]
7. Exposure to an Extended-Interval, High-Dose Gentamicin Regimen in the Neonatal Period Is Not Associated With Long-Term Nephrotoxicity.
Rypdal V; Jørandli S; Hemmingsen D; Solbu MD; Klingenberg C
Front Pediatr; 2021; 9():779827. PubMed ID: 34917565
[No Abstract] [Full Text] [Related]
8. Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.
van Velzen AJ; Uges JWF; Heijerman HGM; Arets BGM; Nuijsink M; van der Wiel-Kooij EC; van Maarseveen EM; van Zanten GA; Pullens B; Touw DJ; Janssens HM
Br J Clin Pharmacol; 2019 Sep; 85(9):1984-1993. PubMed ID: 31112621
[TBL] [Abstract][Full Text] [Related]
9. Clinical Relevance and Predictive Value of Damage Biomarkers of Drug-Induced Kidney Injury.
Kane-Gill SL; Smithburger PL; Kashani K; Kellum JA; Frazee E
Drug Saf; 2017 Nov; 40(11):1049-1074. PubMed ID: 28674842
[TBL] [Abstract][Full Text] [Related]
10. Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy.
Koerner-Rettberg C; Ballmann M
Core Evid; 2014; 9():99-112. PubMed ID: 25278817
[TBL] [Abstract][Full Text] [Related]
11. Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis.
Lam J; Vaughan S; Parkins MD
Clin Med Insights Circ Respir Pulm Med; 2013 Nov; 7():61-77. PubMed ID: 24324354
[TBL] [Abstract][Full Text] [Related]
12. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis.
Prayle A; Watson A; Fortnum H; Smyth A
Thorax; 2010 Jul; 65(7):654-8. PubMed ID: 20627927
[TBL] [Abstract][Full Text] [Related]
13. Minimizing the toxicity of aminoglycosides in cystic fibrosis.
Smyth AR
J R Soc Med; 2010 Jul; 103 Suppl 1(Suppl 1):S3-5. PubMed ID: 20573667
[No Abstract] [Full Text] [Related]
14. The applicability of urinary creatinine as a method of specimen normalization in the cystic fibrosis population.
Wagner BD; Accurso FJ; Laguna TA
J Cyst Fibros; 2010 May; 9(3):212-6. PubMed ID: 20227353
[TBL] [Abstract][Full Text] [Related]
15. Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT).
Kern EF; Erhard P; Sun W; Genuth S; Weiss MF
Am J Kidney Dis; 2010 May; 55(5):824-34. PubMed ID: 20138413
[TBL] [Abstract][Full Text] [Related]
16. Colistin in the 21st century.
Nation RL; Li J
Curr Opin Infect Dis; 2009 Dec; 22(6):535-43. PubMed ID: 19797945
[TBL] [Abstract][Full Text] [Related]
17. Fluid, electrolyte and acid-base disorders associated with antibiotic therapy.
Zietse R; Zoutendijk R; Hoorn EJ
Nat Rev Nephrol; 2009 Apr; 5(4):193-202. PubMed ID: 19322184
[TBL] [Abstract][Full Text] [Related]
18. Measurement of urinary N-acetyl-b-D-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics.
Etherington C; Bosomworth M; Clifton I; Peckham DG; Conway SP
J Cyst Fibros; 2007 Jan; 6(1):67-73. PubMed ID: 16844430
[TBL] [Abstract][Full Text] [Related]
19. The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis.
Glass S; Plant ND; Spencer DA
J Cyst Fibros; 2005 Dec; 4(4):221-5. PubMed ID: 16239129
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
